Clinical Trial: Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07624461) titled 'Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang' on May 28.

Brief Summary: The objective of this real-world, prospective observational study is to evaluate the clinical effectiveness of zamerovimab and mazorelvimab injection (a human rabies monoclonal antibody cocktail) administered in combination with a standard rabies vaccine for post-exposure prophylaxis (PEP) in individuals with WHO Grade III rabies exposure in Nanyang City, China.

1. The study primarily aims to assess:

2. The 3-month rabies-free survival rate following PEP initiation.

3. The 1-year long-term rabies...